Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise for recurrent ovarian cancer in early trial

NCT ID NCT02627443

First seen Nov 17, 2025 · Last updated May 22, 2026 · Updated 26 times

Summary

This early-phase study tests a new drug (berzosertib) added to standard chemotherapy for women with ovarian, peritoneal, or fallopian tube cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination works better than chemo alone. About 35 adults with metastatic disease are participating.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida, 32610, United States

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky, 40536, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, 22908, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan, 48334, United States

Conditions

Explore the condition pages connected to this study.